EP0879884A2 - Dérivés de CD4 - Google Patents
Dérivés de CD4 Download PDFInfo
- Publication number
- EP0879884A2 EP0879884A2 EP98109208A EP98109208A EP0879884A2 EP 0879884 A2 EP0879884 A2 EP 0879884A2 EP 98109208 A EP98109208 A EP 98109208A EP 98109208 A EP98109208 A EP 98109208A EP 0879884 A2 EP0879884 A2 EP 0879884A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- polypeptide
- nucleic acid
- hiv
- molecule
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101710090322 Truncated surface protein Proteins 0.000 claims abstract description 82
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 81
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 81
- 229920001184 polypeptide Polymers 0.000 claims abstract description 79
- 230000027455 binding Effects 0.000 claims abstract description 49
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 38
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 37
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 35
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 claims abstract description 24
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 24
- 239000013598 vector Substances 0.000 claims abstract description 20
- 230000006698 induction Effects 0.000 claims abstract description 17
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 119
- 235000001014 amino acid Nutrition 0.000 claims description 58
- 150000001413 amino acids Chemical class 0.000 claims description 47
- 229940024606 amino acid Drugs 0.000 claims description 45
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 235000018102 proteins Nutrition 0.000 claims description 16
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 10
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 235000004400 serine Nutrition 0.000 claims description 10
- 108010041397 CD4 Antigens Proteins 0.000 claims description 9
- 108060003951 Immunoglobulin Proteins 0.000 claims description 9
- 235000004279 alanine Nutrition 0.000 claims description 9
- 102000018358 immunoglobulin Human genes 0.000 claims description 9
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 8
- -1 aromatic amino acid Chemical class 0.000 claims description 8
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 7
- 235000009582 asparagine Nutrition 0.000 claims description 7
- 229960001230 asparagine Drugs 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 6
- 239000004473 Threonine Substances 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 235000008521 threonine Nutrition 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 238000011156 evaluation Methods 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 5
- 235000004554 glutamine Nutrition 0.000 claims description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 4
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 229960004799 tryptophan Drugs 0.000 claims description 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- 239000006035 Tryptophane Substances 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 48
- 241000725303 Human immunodeficiency virus Species 0.000 description 41
- 108020004414 DNA Proteins 0.000 description 18
- 208000015181 infectious disease Diseases 0.000 description 14
- 230000004927 fusion Effects 0.000 description 12
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 11
- 108020001507 fusion proteins Proteins 0.000 description 11
- 102000037865 fusion proteins Human genes 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 239000012634 fragment Substances 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 9
- 108060001084 Luciferase Proteins 0.000 description 8
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 8
- 108010022394 Threonine synthase Proteins 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 102000004419 dihydrofolate reductase Human genes 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 241001515965 unidentified phage Species 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 208000031886 HIV Infections Diseases 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 5
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 4
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000010187 selection method Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 101710205625 Capsid protein p24 Proteins 0.000 description 3
- 102100039556 Galectin-4 Human genes 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 101710177166 Phosphoprotein Proteins 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 101710149279 Small delta antigen Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 241001524679 Escherichia virus M13 Species 0.000 description 2
- 108010039334 HIV Envelope Protein gp120 Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108700026226 TATA Box Proteins 0.000 description 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 108700004025 env Genes Proteins 0.000 description 2
- 101150030339 env gene Proteins 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- NICFBJUIPZQAMU-UHFFFAOYSA-N CC1(C2(CCC2)CCC1)C=C Chemical compound CC1(C2(CCC2)CCC1)C=C NICFBJUIPZQAMU-UHFFFAOYSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102220508665 Ephrin type-A receptor 4_Q40A_mutation Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 108010083930 HIV Receptors Proteins 0.000 description 1
- 102000006481 HIV Receptors Human genes 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 102100034353 Integrase Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000713821 Mason-Pfizer monkey virus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- ZLIBICFPKPWGIZ-UHFFFAOYSA-N pyrimethanil Chemical compound CC1=CC(C)=NC(NC=2C=CC=CC=2)=N1 ZLIBICFPKPWGIZ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to nucleic acid molecules encoding polypeptides that are derived from the human CD4 molecule. These polypeptides display an increased affinity to glycoprotein 120 of HIV. Additionally, and preferably, said polypeptides also decrease or avoid the induction of binding sites for HIV-co-receptors on gp120 and/or on the protein complex consisting of gp120 and said CD4-derived polypeptides.
- the present invention also relates to pharmaceutical and diagnostic compositions comprising said nucleic acids, vectors comprising said nucleic acids and/or said polypeptides. Finally, the present invention relates to methods for selecting polypeptides having the above-recited advantageous properties.
- CD4-positive cells A common feature of different HIV-types and HIV-strains is an infection of CD4-positive cells.
- the CD4 molecule on the surface of human cells is the primary receptor for HIV (Klatzmann et al., Nature 312 (1984), 767-768). This CD4 molecule is only expressed by cells of hematological origin and by cells of the immune system. Furthermore, only this type of cell can be infected by HIV. This tropism of HIV is most likely the main cause for the pathogenicity in the usually deadly cause of the disease (Capon & Ward, Ann. Rev. Immunol. 9(1991), 649-678).
- soluble CD4 molecules can prevent or at least reduce the risk of an HIV infection.
- soluble CD4 could efficiently block the infection by HIV (Deen et al., Nature 331 (1988), 82-84; Smith et al., Science 238 (1987), 1704-1704).
- additional experiments demonstrated that the primary HIV isolates which were not adapted to in vitro conditions could not be efficiently inhibited by soluble CD4 (Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88 (1991), 7056-7060).
- Binding of gp120 to different co-receptors which, as is known so far, all belong to the group of chemokine receptors results in entry of the virus into the cell (Alkhatib et al., Science 272 (1996), 1955-1958). Soluble CD4 molecules could therefore induce binding of gp120 to said co-receptors and thus lead to the infection of co-receptor bearing cells.
- V1-domain the first extracellular domain of CD4 (V1-domain) binds with a high affinity to gp120 (Arthos et al., Cell 57 (1989), 469-481; Chao et al., J. Biol. Chem. 264 (1989), 5812-5817).
- amino acid positions between amino acids numbers 40 and 55 of the CD4-V1-domain appear to be relevant for binding to gp120 (Clayton et al., Nature 335 (1988), 363-366; Landau et al., Nature 334 (1988), 159-162; Mizukami et al., Proc. Natl. Acad. Sci. USA 85 (1988), 9273-9277).
- Rat CD4 mutants comprising the human CD4 sequence in the region of 33 to 62 can inhibit HIV infection of HeLa cells (Simon et al., J. Exp. Med. 177 (1993), 949-954).
- One of the known data is that the exchange of glutamine in position 40 by alanine enhances binding of CD4 to gp120 by a factor of 2 (Ashkenazi et al., loc. cit.).
- the present invention relates to a nucleic acid molecule encoding a polypeptide being derived from the human CD4 molecule but differing therefrom by (a) a tryptophane or tyrosine residue or another aromatic amino acid instead of a threonine residue in position 45.
- a polypeptide being derived from the human CD4 molecule is intended to mean any polypeptide that has the function of binding to gp120 of HIV such as HIV-1 or HIV-2 and comprises preferably at least the V1-domain of CD4. In further embodiments, this term relates to parts of said V1 domain necessary and sufficient to bind to gp120.
- said V1 domain may be altered insofar that binding to gp120 is improved by replacing one or more amino acids which preferably contribute to binding of CD4 to gp120.
- the overall three-dimensional structure of at least the V1 domain of CD4 should, however, be retained.It is further envisaged that other fragments of CD4 are covered by the above-recited term such as fragments comprising the V1 and V2 domains of CD4.
- the above-recited term further comprises fusion proteins of CD4 or fragments thereof with different (poly)peptides. These different (poly)peptides may be advantageously immunoglobulin domains or parts thereof.
- V1 domains with constant regions of IgG-heavy chain gives rise to a molecule that has two binding sites for gp120.
- this and similar constructs give rise to multimerization devices that have particular advantages when used as therapeutic agents.
- the above recited term comprises said altered CD4 molecules or fragments thereof that are chemically covalently or non-covalently bound to unrelated molecules having e.g. carrier or therapeutic functions such as immunoglobulin molecules or domains thereof.
- the exchange of amino acids that are replaced in the CD4 derivatives may be effected according to conventional protocols. Changes on the level of the nucleic acids may be effected using PCR-based randomization of selected amino acid positions (Barbas, Proc. Natl. Acad. Sci. USA 89 (1992), 4457-4461).
- amino acid positions 39, 40, 41, 42, 45, 46, 47, 48, 50, 52 and 53, (Fig. 3 and Fig. 11) which are non-conserved amino acids in CD4-molecules of different mammalian species, may be useful for testing the effect of an exchange of said amino acids with regard to the binding properties of CD4 to gp120. It was furthermore expected that an exchange of these amino acids by different ones would not result in an overall destruction of the three-dimensional structure of the CD4 derivatives.
- the above-recited positions were randomized starting from molecules in which wild-type glutamine 40 was replaced by alanine.
- CD4 derivatives which comprise the V1 domain were expressed as a part of the coat protein III of bacteriophage M13 (Gram et al., Proc. Natl. Acad. Sci. USA 89 (1992), 3576-3580).
- the genetic code of each special CD4 variant is in this method contained in the respective bacteriophage.
- the resulting bacteriophage can be concentrated to a density of 10 12 per ml.
- gp120 may be bound to a solid phase and subsequently incubated with the concentrated bacteriophage library.
- the bound bacteriophage are subsequently specifically eluted and after infection of E. coli bacteria reamplified.
- the two or more fold repetition of this procedure results in the isolation of CD4 derivatives comprising the V1 domain with a high affinity to gp120.
- the polypeptide encoded by the nucleic acid molecule of the invention results in the decrease or preferably avoidance of the induction of binding sites for HIV co-receptors on gp120 and/or on the protein complex consisting of gp120 and said CD4 derivatives.
- said CD4 derivatives provide a basis for the selection of such molecules by, for example, further rounds of mutagenesis.
- said nucleic acid molecules also differ from the human CD4 molecule by (b) a proline residue instead of a serine residue in position 42.
- said nucleic acid molecule encodes a polypeptide that further differs from said human CD4 molecule by (c) a replacement of the amino acid asparagine in position 52 by a different amino acid.
- Said different amino acid is advantageously a small amino acid.
- amino acid in position 52 is alanine or serine.
- said polypeptide further differs from said human CD4 molecule by (d) a replacement of the amino acid aspartic acid in position 53 by a different amino acid.
- said different amino acid is glycine, serine, threonine, asparagine, glutamic acid or glutamine
- An additional preferred embodiment of the present invention relates to a nucleic acid molecule wherein said polypeptide is further characterized by asparagine, serine or threonine in position 39, an alanine, serine or tyrosine residue in position 40, a glycine residue in position 41, arginine in position 46, a glycine residue in position 47, a proline residue in position 48, and/or glutamic acid or alanine in position 50 including any combinations thereof.
- the nucleic acid molecule according to the invention encodes a polypeptide that further differs from human CD4 in that a sequence comparable to an immunoglobulin domain hypervariable loop is inserted into at least one V- ⁇ -CDR homologous region of the CD4 molecule.
- the V- ⁇ -CDR homologous region of CD4 is described in Wang et aL., Nature 348 (1990), 411-418 and is advantageously homologous to the CDR-1 or the CDR-3 of the kappa light chain variable domain. This embodiment of the invention is particularly advantageous since it can be used to dramatically increase the binding capacity of soluble CD4 molecules to gp120.
- the inclusion of said loop is expected to significantly contribute to the decrease and preferably the avoidance of the induction of binding sites for HIV co-receptors on gp120 and/or on the protein complex consisting of gp120 and the CD4 derivative of the invention.
- the immunoglobulin-like hypervariable loop after insertion into said at least one V- ⁇ -CDR homologous region may be mutagenized according to conventional protocols and selected for increased binding to gp120 and for the above-recited decrease or avoidance of said induction by methods that are known in the art.
- the hypervariable loop may vary in length and/or sequence from a naturally occurring loop both prior to and after the mutagenesis step.
- the phage display method that is advantageously used for selecting appropriate polypeptides has the particular advantage that extremely large numbers of clones can be tested for their properties.
- nucleic acid molecules which are DNA or RNA.
- the nucleic acid molecules are advantageously cDNA, synthetic DNA, semi-synthetic DNA or genomic DNA.
- the invention further relates to a vector comprising the nucleic acid molecule of the invention.
- the vector of the invention may advantageously be an expression vector.
- vectors that are useful for gene therapy are preferred.
- the genomic information of the above-recited CD4 derivatives may be used for the intracellular prevention of the production of new HIV in certain target cells of an organism. This can, for example, be effected by the intracellular production of CD4 derivatives under the control of an HIV-LTR in CD4 positive cells.
- Another possibility for the use of the vector of the invention in gene therapy is the in vivo stimulation of autologous cells for the synthesis and release of soluble CD4 derivatives. These derivatives would then prevent or at least significantly reduce the infection of further cells by HIV in the bloodstream and/or lymphoid tissue.
- a further option for the use of the vector of the invention in gene therapy is the generation of preferably autologous hematopoietic stem cells that will differentiate into CD4 positive cells, preferably T cells and mononuclear phagocytes that instead of wild-type CD4 express a CD4 dervative of the invention making them reistant or at least significantly less susceptible to HIV infection.
- the present invention also relates to host cells transformed with the vector of the invention.
- Said host cells may be bacterial cells and preferably E. coli cells.
- said hosts may be eucaryotic cells and preferably yeast cells, insect cells that may be infected with baculoviruses or mammalian cells, for example, non-transformed primary human cells. The latter cells may be advantageously used for gene therapy.
- said hosts may be transgenic animals or plants which may be used for the production of the polypeptide of the invention.
- the present invention relates to a method of producing a polypeptide encoded by the nucleic acid molecule of the invention comprising culturing the host according to the invention and recovering the produced polypeptide.
- the details of the method of production for example, the composition of the culturing medium will eventually depend on the host that is used for producing the polypeptide. If cells are used as host organisms and said host organisms are cultured in liquid medium, the polypeptide may, depending on the specific vector construction and the host cell used, either be exported into the medium or retained in the cell or both. The person skilled in the art will, of course, take these prerequisites into account when recovering the polypeptide of the invention.
- the present invention relates to a polypeptide encoded by the nucleic acid of the invention or produced by the method of the invention.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising the nucleic acid according to the invention, the vector of the invention and/or the polypeptide of the invention and optionally a pharmaceutically acceptable carrier and/or diluent.
- the pharmaceutical composition of the invention may be advantageously used for preventing or treating HIV infections.
- the dosage regimen will be determined by the attending physician considering the condition of the patient, the severity of the disease and other clinical factors. Generally, the regimen as a regular and administration of the pharmaceutical composition will depend on the actually pharmaceutically active ingredient that is contained in the pharmaceutical composition. In the case of the polypeptide of the invention, it would usually be in the range of 100mg or less per kg of body weight per day. Administration of the suitable compositions may be effected in different ways, e.g., by intravenous, intraperitoneal, subcuteneous, intramuscular or other routes.
- the pharmaceutical composition of the invention is a vaccine.
- the present invention also relates to diagnostic compositions comprising the nucleic acid of the invention, the vector of the invention and/or the polypeptide according to the invention.
- the diagnostic composition of the invention can be advantageously employed for specifically capturing and thus enriching HIV particles from samples, for example, blood samples, of HIV patients. The enrichment may be followed by a highly sensitive determination of the viral load of HIV in the patient.
- the diagnostic composition of the invention may be used for measuring soluble gp120 protein in samples from a patient. It may further be used for the ex vivo or in vivo diagnosis of organs and tissues with high gp120 expression. The result of such a diagnosis would indicate HIV replication by in-vivo targeting and subsequent imaging.
- the invention further relates to a method of selecting a polypeptide being derived from human CD4 and having an enhanced affinity to gp120 comprising:
- the present invention relates to a method of selecting a polypeptide being derived from human CD4 and having the capacity to significantly decrease and preferably avoid the induction of binding sites for HIV-co-receptors on gp120 and/or on the protein complex consisting of gp120 and said CD4-derived polypeptide comprising:
- said method of the invention further comprises the steps of
- evaluation and/or selection steps are effected with at least two gp120 molecules obtained from different HIV isolates. It is expected that the alternating or simultaneous selection using at least two gp120 molecules from different HIV isolates make the generation of escape mutants in an in vivo application less likely.
- the CD4 derivatives produced in accordance with the method of the invention are accordingly expected to bind to a large number and preferably all naturally occurring HIV strains.
- Naturally, more than two gp120 molecules obtained from different HIV isolates may be used in the method of the invention.
- At least one of said gp120 molecules is gp120IIIB (gp120LAI) or gp120MN.
- both of said molecules are used in the selection/evaluation steps. Both isolates are well known in the art.
- the selection/evaluation may be effected using conventional methods such as ELISA methods and/or panning methods such as described in the appended examples.
- an additional elution step using potassium rhodanide is employed. This step secures the elution of phages binding with an ultrahigh affinity.
- the present invention relates to polypeptides that are obtainable by the method of the invention.
- Example 1 Construction of a phage library displaying CD4-V1 mutants
- a phage library of human CD4-V1 mutants was constructed using degenerated primers in amino acid positions: 41, 42, 45, 48, 52, and 53 (Fig. 1). Amino acid positions are used according to Wang et al., loc. cit. The sequences of the used primers are shown in the Table 1. The randomization was performed in two steps. In the first step the positions 52 and 53 were randomized using a 3'-V1 primer that introduces a SpeI restriction site and the 5'-CDR2 primer that introduces a XhoI, a HindIII and a XbaI restriction site. Using a plasmid containing the full length cDNA of human CD4, a 176 bp DNA fragment was amplified by PCR.
- the used PCR protocol was: denaturation at 94°C, 5 minutes followed by 30 cycles of denaturation (94°C, 1 minute), primer annealing 52°C, 1 minute, and Taq polymerization (72°C, 30 seconds), followed by 5 minutes final polymerization at 72°C.
- the 176bp PCR products were purified by agarose gel electrophoresis and cut with restriction enzymes SpeI and XhoI.
- the digested DNA was purified again by agarose gel electrophoresis and ligated to the SpeI and XhoI restriction sites of the phagemid vector pComb3H (derived from pComb3, Barbas, Proc. Natl. Acad. Sci. U.S.A.
- the resulting CD4-3'V1 library with 1024 different DNA species was transformed into electrocompetent E. coli XL1 blue by electroporation. More than 1x10 8 bacterial transformants expressing the pComb3H amp gene and harbouring the inserted 3'V1 region were immediately generated after the transformation. Following over night growth of these bacteria, the plasmid DNA was purified and used for the generation of a V1 library in the second randomization step.
- the 5'V1 primer introducing a Sac I restriction site and the 3'CDR2 primer introducing AvrII and HindIII restriction sites were used (Fig. 1, Table 1).
- the amplified 169 bp DNA was purified and digested with the restriction enzymes SacI and HindIII.
- This DNA was ligated with the 3'V1 plasmid library generated in the step 1 (also digested with the restriction enzymes SacI and HindIII) and introduced into the E. coli cells by electroporation. Multiple electroporations were performed and bacterial transformants were pooled. The number of transformants with the randomized CD4V1 region exceeded 2x10 9 (the NNS-based randomization of 6 amino acid positions gives rise to 1x10 9 possible DNA species).
- the phagemid pComb3H contains the CD4-V1 region fused with a geneIII fragment of the single stranded bacteriophage M13.
- the complete product of geneIII is necessary for phage infectivity and is termed coat proteinIII (cpIII).
- the infection of the phagemid pcomb3H transformants with the helper bacteriophage VCSM13 (1x10 12 pfu per 100 ml bacterial culture) gives rise to infective M13 bacteriophages that express the CD4V1-cpIII fusion protein (Fig. 2). After overnight incubation at 37°C, phage particles were harvested from the bacterial supernatant by polyethylene glycol/NaCl precipitation.
- TBS/BSA Tris buffered solution/1% bovine serum albumin
- Example 2 Expression of selected CD4 variants as a fusion protein with human IgG1
- the randomized regions of the selected CD4 variants were cut with restriction enzymes BsrgI and MfeI and inserted into the V1V2 fragment of CD4 (Fig. 4).
- the V1V2 mutants and the wild typ V1V2 were fused to the hinge-CH2-CH3 domain of the human IgG1 according to the molecular design of the CD4-IgG1-derivative described by Byrn, Nature 344 (1989) 667-670) and cloned into the EcoRI/SaII sites of pEF-DHFR (Mack, Proc. Natl. Acad. Sci. U.S.A. 92 (1995), 7021-7025).
- Example 3 Construction of an in vitro test system for inhibition of HIV env induced fusion
- CHO cells were transfected with expression plasmids of two HIV co-receptors: CXCR4 and CCR5 (DHFR selection marker, Fig. 6). These cells were co-transfected with expression plasmids of the wild type human CD4 or CD4 molecules with replacements of the selected V1 variants. The ability of diverse HIV subtypes to infect these cells can be investigated.
- DHFR deficient CHO cell line purchased from ATCC.
- the wild type CD4 and its derivatives were stably expressed as whole transmembrane proteins (Fig. 6) on CHO cells.
- the CD4 and CD4 derivatives were cloned into the expression vector pEF-ADA derived from the expression vector pEF-DHFR (Mack, Proc. Nat. Acad. Sci. U.S.A. 92 (1995) 7021-7025)by replacing the cDNA encoding murine dihydrofolate reductase (DHFR) by that encoding murine adenosine deaminase.
- DHFR murine dihydrofolate reductase
- This plasmid was transfected for stable expression into DHFR-deficient CHO-cells by means of electroporation (Sambrook (Molecular Cloning; A Laboratory Manual, 2 nd edition, Cold Spring Harbour Laboratory Press, Cold Spring Harbor, NY (1989)); subsequent selection was carried out in 11-AAU-medium containing 0,1 ⁇ M deoxycoformycin (dCF)as described by Kaufman-RJ (Meth. Enzym.185 (1990) 537-566) and supplemented with nucleosides.
- dCF deoxycoformycin
- These primarily transfected CHO cells were further stably transfected with a pEF-DHFR expression plasmid (Mack, Proc. Natl. Acad. Sci. U.S.A.
- the other fusion partner was the mouse mastocytoma cell line P815. These cells express the luciferase gene under the control of the MRG5-promotor which is inducible by the fusion protein GAL4-VP16.
- a DNA fragment consisting of the MRG5-promotor, luciferase and the polyadenylation site of SV40 was cloned into the SaII and SacI sites of pHyg ⁇ (Fig. 13). This vector additionally contains the hygromycine B resistance gene.
- This plasmid was introduced into P815 cells which were subsequently selected at 300 ⁇ g/ml hygromycine B.
- Several cellular clones were established and tested for luciferase activity by transient transfection with the GaI4-VP16-expression plasmid described below followed by measuring the luciferase activity with a commercial kit (Berthold). Transient transfection was carried out according to standard procedures (Sambrook (Molecular Cloning; A Laboratory Manual, 2 nd edition, Cold Spring Harbour Laboratory Press, Cold Spring Harbor, NY (1989)). A cell clone exhibiting a high level of inducible reporter gene activation was chosen for the further work (P815 cell clone 1.2).
- the env gene of HIV isolates LAI or MN was expressed in the neomycine resistance plasmid pEF-Neo-CTE, respectively.
- This vector was constructed to express the env gene in eukaryotic cells in a rev independent manner. Normally the transport of the env transcript from the nucleus into the cytoplasma is impaired and needs rev activity since HIV env contains intron sequence elements (Emerman-M et al., Cell. 1989 57(7): 1155-65). The nuclear transport and subsequent translation can be enhanced by the constitutive transport element (CTE) of Mason-Pfizer-Monkey virus (Ernst-RK et al., Mo-Cell-Biol.
- CTE constitutive transport element
- the core 153 bp CTE sequence was synthesized as double-stranded oligonucleotide and cloned into the eucaryotic expression vector pEF-NEO between the neomycine resistance gene and its polyadenylation site.
- the transfection into P815-cells of env cloned into pEF-Neo-CTE gave rise to stable expression of env which was proved by antibody staining (flowcytometry) and the env specific fusion assay.
- the inserted CTE sequence was:
- CD4-variant 1 shows reduced fusion activity with both, gp120 (env) LAI and gp120 (env) MN, compared to wild type CD4, thus indicating decreased induction of HIV-coreceptor binding sites during interaction with gp120.
- the IgG1-CD4 and its derivatives were tested in an in vitro HIV inhibition test.
- the CD4 positive human T cell line H9 was used as target cells for infection with HIV isolate LAI. 10 5 H9 cells each well were incubated in 48 well plates over night.
- the IgG1-CD4 and its derivatives were separately incubated in several concentrations with 100 TCID/50 of HIV-LAI for 30 minutes in 37°C. This virus solution was added to the target cells and incubated over night. 24 hours after the infection attempt the supernatant of the H9 cells was removed and refilled 3 times in order to reduce the background of HIV antigen value. 10 days after the infection attempt the HIV p24 concentration was measured in the cell supernatant by a commercial kit.
- Example 5 Purification and affinity determination of selected CD4 variants as a fusion proteins with human IgG1
- CHO cells secreting the IgG1 fusion proteins of CD4- and CD4 variants were incubated in roller bottles in a medium containing 10% dialysed FCS and 500nM methotrexate until confluence was achieved. This medium was then discarded and replaced by a medium containing 0,5% dialysed FCS and 500mM methotrexate. 1,5 liters of medium were harvested in a 9 day periode.
- Purification of CD4-IgG1 fusion proteins was carried out by protein A sepharose chromatography according to standard procedures. Multiple eluates of protein A-sepharose were screend in ELISA and SDS-PAGE for fractions with recombinant protein of high purity. The main pure fraction was concentrated (to approximately 1mg/ml), filtered to obtain a sterile solution and analyzed by SDS-PAGE ( Figure 12).
- CD4-variants 1,2,3 and 5 exhibit increased affinity to gp120LAI compared to wild type CD4 (WT CD4), with variant 3 also showing slightly increased affinity to gp120MN. Furthermore, all variants have improved on-rates to gp120LAI and gp120MN except for the interaction of variant 5 with gp120LAI.
- Example 6 Off-rate selection of CD4 variant binding to gp120LAI and gp120MN by the mean of phage display and competitive displacement by wild type IgG1-CD4
- the first procedure of phage display and phage selection resulted in the selection of CD4-variants with a higher on-rate to gp120LAI and gp120MN compared with the wild type CD4.
- a new phage library was created in order to perform an off-rate selection of phages expressing CD4 variants.
- the gp120 binding domain of the CD4 variant 1 was degenerated by random primers and a phage library was created.
- the amino acid positions 39, 40, 46, 47 and 50 were degenerated by the NNS sequences in order to obtain all possible combinations of amino acids.
- the position 45 was degenerated by the sequences TWG and TGG in order to obtain the aromatic amino acids (Phenylalanine, tyrosine and tryptophan).
- the position 52 was degenerated by the nucleotide sequences KCA in order to obtain alanine or serine.
- the amino acid position 53 was degenerated by the nucleotide sequences AVC and SAS in order to obtain the amino acids: serine, threonine, asparagine, glutamic acid, aspartic acid, glutamine and histidine (see table for the used primers).
- the theoretical nucleic acid sequence diversity of the whole library was calculated to 1,5 x 10 9 .
- the procedure of library construction The 5' region of CD4 variant 1 (the dominant variant in the first phage selection procedure, depicted as Sequ. 1 in Fig.3)was PCR-amplified with the primers 5 ⁇ V1 and 3'CDR2-2.
- the amplified DNA species were cloned into the XhoI and SacI sites of the pComb3H.
- the 3' region was amplified with the primers 3'V1 together with only one of the primers 5'CDR2-2/1, 5'CDR2-2/2, 5'CDR2-2/3 or 5'CDR2-2/4 (for primer sequences see table 4).
- the resulting 3'fragments were subsequently cloned into the pBluescriptKS by the SpeI and ApaI sites in order to create separate 3'sublibaries in the bacteria XL1Blue.
- the plasmids of these separate sublibraries were isolated and precisely balanced according to the mathematical possible nucleotide sequences in order to not over-represent certain sequence motives in the whole library.
- the balanced 3'library was then digested with SpeI and ApaI and cloned into the already created pComB3H-5'library. 4x10 9 transfectants were created using the electocompetent XL1-Blue bacteria purchased from Stratagene.
- Phage selection procedure The phage production and selection was performed as described in example 1 except for the incubation conditions described in table 5.
- gp120 was coated on Costar high binding A/2 plates overnight at 4 ⁇ c.
- the phage supernatant of 200 or 100 ml bacterial culture was harvested precipitated and resuspended in 10 ml TBS/1%BSA. 600 to 300 ⁇ l of this phage suspension was given to the wells coated with gp120LAI or gp120MN.
- the phage suspension was incubated 2 hours or 15 minutes in the gp120 coated wells (see table).
- the unbound phages were washed with TBS/0,05%tween20 solution.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98109208A EP0879884A3 (fr) | 1997-05-20 | 1998-05-20 | Dérivés de CD4 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97108162 | 1997-05-20 | ||
EP97108162 | 1997-05-20 | ||
EP98109208A EP0879884A3 (fr) | 1997-05-20 | 1998-05-20 | Dérivés de CD4 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0879884A2 true EP0879884A2 (fr) | 1998-11-25 |
EP0879884A3 EP0879884A3 (fr) | 2004-02-25 |
Family
ID=31189544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98109208A Withdrawn EP0879884A3 (fr) | 1997-05-20 | 1998-05-20 | Dérivés de CD4 |
Country Status (1)
Country | Link |
---|---|
EP (1) | EP0879884A3 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5109123A (en) * | 1988-06-14 | 1992-04-28 | Dana Farber Cancer Institute | Alteration of ability of soluble CD4 fragments to bind HIV |
WO1994014847A1 (fr) * | 1992-12-24 | 1994-07-07 | The Regents Of The University Of California | Immunoglobulines produites par genie genetique |
-
1998
- 1998-05-20 EP EP98109208A patent/EP0879884A3/fr not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5109123A (en) * | 1988-06-14 | 1992-04-28 | Dana Farber Cancer Institute | Alteration of ability of soluble CD4 fragments to bind HIV |
WO1994014847A1 (fr) * | 1992-12-24 | 1994-07-07 | The Regents Of The University Of California | Immunoglobulines produites par genie genetique |
Non-Patent Citations (2)
Title |
---|
A. ASHKENAZI ET AL.: "Mapping the CD4 binding site for human immunodefficiency virus by alanine-scanning mutagenesis" PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 7150-7154, XP002265636 * |
M. BOWMAN ET AL.: "Identification and structural analysis of residues in the V1 region of CD4 involved in interaction with human immunodeficicency virus envelope glycoprotein gp120 and class II major histocompatibility molecules." PROC. NATL. ACAD. SCI USA, vol. 87, 1990, pages 9052-9056, XP001176840 * |
Also Published As
Publication number | Publication date |
---|---|
EP0879884A3 (fr) | 2004-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5597895A (en) | Transdominant tat mutants and uses thereof | |
KR100337069B1 (ko) | 항-hiv모노클로날항체 | |
US8598317B2 (en) | Muteins of tear lipocalin with affinity for the T-cell coreceptor CD4 | |
CN108728459B (zh) | 靶向cd19的嵌合抗原受体并联合表达il-15的方法和用途 | |
DE69519746T2 (de) | Protein aufspüren auf hiv virion auf basis von hiv-1 vpr fusionmolekulen | |
US20240101616A1 (en) | Dap10/12 based cars adapted for rush | |
CN108864286B (zh) | 靶向cd19的嵌合抗原受体及联合表达抗pd1抗体可变区的方法和及其用途 | |
US7109317B1 (en) | FK506-based regulation of biological events | |
US20060240516A1 (en) | Interacting polypeptide comprising a heptapeptide pattern and a cell penetration domain | |
EP0879884A2 (fr) | Dérivés de CD4 | |
US6287572B1 (en) | Anti-HIV peptides and proteins | |
WO2021143733A1 (fr) | Protéine de fusion, son procédé de préparation et son utilisation | |
EP0917585B1 (fr) | VECTEURS DE DéLIVRANCE PERMETTANT D'INHIBER LA CROISSANCE VIRALE OU TUMORALE | |
JPH1029952A (ja) | ヒト免疫不全ウイルス感染の制御用組成物および制御方法 | |
WO1998037089A9 (fr) | Peptides et proteines anti-vih | |
CN114907490B (zh) | 强效双功能hiv进入抑制剂及其应用 | |
WO1996037234A1 (fr) | Immunisation intracellulaire | |
WO1996028189A1 (fr) | Gene de fusion transdominant double et proteine | |
AU1603900A (en) | Fk506-based regulation of biological events | |
WO2024153120A1 (fr) | Fragment d'ectodomaine pd1 muté, car le contenant et cellule nk | |
AU685560B2 (en) | Antiviral composition of viral protein trans-dominant variants | |
US20240150472A1 (en) | Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody | |
US20060067948A1 (en) | Viral vectors | |
AU626007B2 (en) | Dna sequences, recombinant dna molecules and processes for producing soluble t4 proteins | |
KR20240023127A (ko) | 망막 장애 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 12Q 1/68 B Ipc: 7A 61K 39/00 B Ipc: 7C 12N 15/12 B Ipc: 7A 61K 38/00 B Ipc: 7C 07K 14/705 A |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
17P | Request for examination filed |
Effective date: 20040824 |
|
AKX | Designation fees paid |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AXX | Extension fees paid |
Extension state: SI Payment date: 20040824 Extension state: RO Payment date: 20040824 Extension state: MK Payment date: 20040824 Extension state: LV Payment date: 20040824 Extension state: LT Payment date: 20040824 Extension state: AL Payment date: 20040824 |
|
17Q | First examination report despatched |
Effective date: 20050425 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20081202 |